Diabetes News

The European Commission has approved an update to the liraglutide (Victoza) EU label that expands the indication to reflect both improving blood sugar and cardiovascular (CV) events as integral parts of type 2 diabetes treatment.

Results of the DEVOTE trial investigating the cardiovascular (CV) safety profile of long-acting insulin, insulin degludec (Tresiba), in adults with type 2 diabetes were presented at the American Diabetes Association (ADA) congress. 

The risk of developing type 2 diabetes by age 20 was 12 times as high in severely obese American Indian children aged five to nine years of age as in normal-weight youth in that age range, according to a new study.

Sodium-glucose transporter-2 (SGLT2) inhibitors are associated with lower rates of death and hospitalisation for heart failure when used to treat patients with type 2 diabetes

New findings from a post-hoc analysis of the LEADER cardiovascular (CV) outcomes trial were presented recently at the 77^th annual Scientific Sessions of the American Diabetes Association (ADA).

Two new studies have found an increased risk of heart problems, such as heart attack and chest pain, in women with diabetes compared to men.

Five million people in England have blood glucose levels indicating a high risk of developing type 2 diabetes, according to a new report published by Public Health England (PHE).

BAME patients are under-represented in randomised controlled trials, despite being more susceptible to and have a higher incidence to type 2 diabetes compared to the wider population, new research has found.

An international collaboration, funded by Qatar National Research Fund (QNRF), between the University of Bristol and Anti-Doping Laboratory Qatar (ADLQ), has revealed that fat stem cells in healthy obese individuals can store fat more efficiently than those with increased risk of diabetes.

New data presented recently at the Diabetes UK Professional Conference shows gaps in patients’ understanding about the potential side effects of treatments for type 2 diabetes, such as hypoglycaemia.